This prospective randomized controlled pilot study was conducted in a tertiary referral university hospital to evaluate whether the administration of letrozole in the luteal phase of stimulated IVF cycles, through a decrease in oestradiol, could alter the suppressed LH levels in the luteal phase. Following oocyte retrieval, six oocyte donors aged < or = 36 years were randomized to receive either 5 mg letrozole (n = 3) or placebo (n = 3). On days 4, 7 and 10 after human chorionic gonadotrophin (HCG) administration, oestradiol levels of the letrozole group were significantly lower compared with the placebo group (P = 0.008, P =0.005 and P =0.004, respectively). LH and progesterone values were comparable between both groups at all time points measured. This study demonstrates that the addition of 5 mg of letrozole in the luteal phase of stimulated donor IVF cycles significantly alters the oestradiol levels on days 4, 7 and 10 after HCG administration for final oocyte maturation. The progesterone and LH profiles of patients treated with letrozole during the same period were not altered compared with the placebo group.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s1472-6483(10)60212-x | DOI Listing |
Arch Gynecol Obstet
January 2025
Reproductive Medicine Research Center, The Sixth Affiliated Hospital, Sun Yat-Sen University, No. 17 Shou-gou-ling Rd., Tianhe District, Guangzhou, 510000, China.
Purpose: To investigate an optimal strategy by assessing the effectiveness of varying follicular sizes on trigger day during luteal phase stimulation protocol and provide evidence for personalized protocol adjustment.
Methods: This was a retrospective study including a total of 661 patients who had started their in vitro fertilization cycle with a luteal phase stimulation (LPS) protocol during 2015-2023. We classified patients into groups according to the size of the dominant proportion of follicles on the human chorionic gonadotropin (hCG) trigger day: large, medium, and small.
Oestrogen and progesterone fluctuate cyclically in women throughout their adult lives. Although these hormones cross the blood-retinal barrier and bind to intraocular receptors, their effects remain unclear. We present the first review to date on associations between posterior pole structures-specifically the macula, choroid, and optic disc-and both the menstrual cycle and post-menopausal period, utilising multimodal imaging techniques in healthy adult non-pregnant women.
View Article and Find Full Text PDFPhysiol Res
December 2024
Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
An important part of the side effects of combined oral contraceptives (COC) usage is its psychological impact, which includes mood changes, anxiousness and depression. The psychological impacts are expected to be caused by physiological fluctuations of sex hormone levels during the menstrual cycle; this cycling is, however, suppressed in COC users. In our study, we assessed the differences in emotional awareness and anxiousness between women long term users of anti-androgenic COC (AA) and women with no COC use in their medical history (C).
View Article and Find Full Text PDFFood Sci Nutr
January 2025
Seed cycling therapy (SCT) involves the consumption of specific seeds during the follicular and luteal phases of the menstrual cycle to help balance reproductive hormones. This study aimed to investigate the effects of SCT on healthy female Wistar albino rats to prevent hormonal imbalances. For SCT, a seed mixture (SM1) consisting of flax, pumpkin, and soybeans (estrogenic seeds) was administered at doses of 5.
View Article and Find Full Text PDFHum Reprod Open
January 2025
Regional Center of Pharmacovigilance, Pharmacology Department, Cochin Hospital, AP-HP.Centre-Université Paris Cité, Paris, France.
Study Question: Is there an association between dydrogesterone exposure during early pregnancy and the reporting of birth defects?
Summary Answer: This observational analysis based on global safety data showed an increased reporting of birth defects, mainly hypospadias and congenital heart defects (CHD), in pregnancies exposed to dydrogesterone, especially when comparing to progesterone.
What Is Known Already: Intravaginal administration of progesterone is the standard of care to overcome luteal phase progesterone deficiency induced by ovarian stimulation in ART. In recent years, randomized controlled clinical trials demonstrated that oral dydrogesterone was non-inferior for pregnancy rate at 12 weeks of gestation and could be an alternative to micronized vaginal progesterone.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!